🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
India flag India · Delayed Price · Currency is INR
2,648.00
+39.50 (1.51%)
Nov 20, 2026, 3:28 PM IST

Glenmark Pharmaceuticals Cash Flow Statement

Millions INR. Fiscal year is Apr - Mar.

Operating Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Net Income
14,51313,61910,471-15,0172,9729,417
Depreciation & Amortization
6,2265,4024,5584,7923,8101,613
Other Amortization
333.16333.16302.361,5172,3033,254
Loss (Gain) From Sale of Assets
31.21170.1825.42-8.26-57.2564.64
Loss (Gain) From Sale of Investments
-0.06-0.250.27-7,450-0.26-149.81
Stock-Based Compensation
317.51268.05-91.6749.6267.7479.16
Provision & Write-off of Bad Debts
198.86201.2530.97176.5118.72298.74
Other Operating Activities
3,19418,9291,36415,9281,4992,122
Change in Accounts Receivable
-15,280-17,505-14,2039,695-8,487-5,493
Change in Inventory
-3,473-7,523-4,508-5,139-3,752-2,034
Change in Accounts Payable
5,40227,046-7,787-7,3441,662847.57
Change in Other Net Operating Assets
-7,403-6,4891,562-5,182-167.731,067
Operating Cash Flow
4,06134,450-8,276-2,6546,25411,087
Operating Cash Flow Growth
-85.45%----43.59%-1.99%

Investing Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Capital Expenditures
-12,326-13,577-7,507-8,984-6,078-7,901
Sale of Property, Plant & Equipment
78.8523.324.220.8572.2915.8
Divestitures
---54,496--
Investment in Securities
92.31-1.927,35770.51-10.08-100.18
Other Investing Activities
1,079723.36146.675.31230.514,653
Investing Cash Flow
-11,076-12,83220.9445,609-5,285-3,333

Financing Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Short-Term Debt Issued
--8,3394,811--
Long-Term Debt Issued
--5,072-11,63221,301
Total Debt Issued
8,587-13,4124,81111,63221,301
Short-Term Debt Repaid
--17,157---200-1,417
Long-Term Debt Repaid
--6,416-2,462-37,539-6,198-31,201
Lease Payments
-1,522-1,117-1,055-1,044-1,066-1,010
Total Debt Repaid
-10,628-23,573-2,462-37,539-6,398-32,618
Net Debt Issued (Repaid)
-2,041-23,57310,950-32,7285,234-11,317
Issuance of Common Stock
14.317.59-12--
Common Dividends Paid
-2,123-1,410-704.42-704.52-703.86-926.95
Other Financing Activities
-2,014-2,111-2,375-5,641-5,3057,040
Financing Cash Flow
-6,164-27,0877,870-39,061-774.56-5,205

Net Cash Flow

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Foreign Exchange Rate Adjustments
-390.89459.55558.93176.79123.87175.5
Miscellaneous Cash Flow Adjustments
----1,9186.68-
Net Cash Flow
-13,569-5,010174.372,1523252,724

Free Cash Flow

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Free Cash Flow
-8,26520,873-15,783-11,638176.293,185
Free Cash Flow Growth
-----94.47%-10.64%
Free Cash Flow Margin
-5.17%12.25%-11.81%-9.20%0.15%2.59%
Free Cash Flow Per Share
-29.2873.94-55.93-41.240.6311.29
Levered Free Cash Flow
-16,17812,223-16,06943,246-11,6041,853
Unlevered Free Cash Flow
-14,91713,527-14,77546,471-9,4233,716
Free Cash Flow After Leases
-9,78719,757-16,839-12,682-889.232,176

Additional Metrics

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash Interest Paid
2,0142,1112,0745,1683,1152,505
Cash Income Tax Paid
7,5047,8306,80110,4756,4055,584
Change in Working Capital
-20,753-4,471-24,936-7,970-10,745-5,613